Acute-on-Chronic Liver Failure (ACLF) is a critical medical condition characterised by the sudden deterioration of liver function in individuals with underlying chronic liver disease. This complex syndrome is marked by a rapid onset of severe liver dysfunction and is often associated with multiple organ failures. ACLF requires immediate medical attention and intervention, posing a high mortality risk. Effective management strategies and early detection are crucial in improving the prognosis for patients with ACLF, making it a significant focus in gastroenterology and hepatology.

Target audience

• Gastroenterologists (in training)
• Hepatologists (in training)
• Intensive care specialists

Pancreatic cancer is a highly aggressive malignancy, often asymptomatic in its early stages, making early detection challenging. Risk factors are tobacco use and certain genetic mutations. Pancreatic cancer has a poor prognosis, with a low overall survival rate.

The course includes comprehensive PPT slides and bespoke video presentations. It starts with an introduction to pancreatic cancer, covers clinical presentations and diagnostic workup, as well as basic therapeutic approaches of patients with pancreatic cancer. Furthermore, information on the surveillance of patients with an increased risk of pancreatic cancer will be presented.

Target audience

The target audience for this course are gastroenterologists (in training), fellows in training, Medical students (in training), general practitioners, nurses, dieticians, physicians of other specialities and basic scientists in gastroenterology who want to gain more knowledge on pancreatic cancer.

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent but largely asymptomatic disease that poses a major challenge to healthcare systems worldwide. Disease severity and outcome vary considerably and those at greatest risk of progression from steatosis and steatohepatitis to cirrhosis and hepatocellular carcinoma need to be identified.

This online course, from the multidisciplinary team of Quentin M. Anstee, Stuart McPherson, Kate Hallsworth and Laura Haigh, provides a comprehensive update on all aspects of NAFLD. After introducing the epidemiology and natural history of NAFLD, the course turns its attention to biomarkers, patient identification and care pathways, dietary and lifestyle interventions, and pharmacotherapy.

The course includes detailed PPT slides and bespoke video presentations, which were filmed in May 2022. The estimated time needed to complete the course, including the final assessment, is 120 minutes.

Target audience

This course is designed for gastroenterologists and/or hepatologists in training, liver pathologists, endocrinologists/diabetologists, primary care physicians, nurses, allied health professionals, basic scientists working in translational biomedicine, and medical students.